ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ginkgo Bioworks has agreed to use its synthetic biology capabilities to improve the production of an unidentified biobased chemical from Sumitomo Chemical and make other Sumitomo products. An earlier agreement between Sumitomo and Zymergen, a Ginkgo competitor, yielded a biobased film for use in displays and touch screens. Both Sumitomo partners are riding high with investors at the moment. Zymergen made a successful initial public offering in May, while Ginkgo is in the process of going public by merging with a special purpose acquisition company, or SPAC.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter